---
id: market_001
type: market
topic: GLP-1 market dynamics
disease: Obesity, Diabetes
molecule: Semaglutide, Tirzepatide
---

Market Intelligence: GLP-1 Agonist Market Explosion Reshapes Pharma Landscape

Date: November 2024

Market Size: The GLP-1 receptor agonist market reached $50 billion in 2024, projected to exceed $130 billion by 2030 (CAGR 17.2%).

Key Players:
- Novo Nordisk (Wegovy/Ozempic): 65% market share, supply constraints ongoing
- Eli Lilly (Mounjaro/Zepbound): Rapidly gaining share, 28% of market
- Emerging competitors: Amgen, Pfizer, Roche in development

Supply Chain Analysis:
- Global peptide manufacturing capacity insufficient
- New facilities require 3-5 years to operationalize
- API shortage expected through 2026

Commercial Dynamics:
- Payer pushback on obesity indication coverage
- Out-of-pocket costs $1,000-1,500/month limiting access
- Compounding pharmacy controversy ongoing

Investment Signal: STRONG BUY for established players. Pipeline entrants face high bar. Watch for oral GLP-1 formulations (Rybelsus) gaining traction.

